Sign in with Google
bullish
SanBio (4592 JP): Better-Than-Expected Operating Loss in FY23; Product Approval Expected in FY24
481 Views17 Mar 2023 10:14
SUMMARY
- SanBio Co Ltd (4592 JP) recorded operating loss of ¥7.9B for FY23, better than guidance of ¥8.1B. For FY24, the company guided for operating loss of ¥4.6B, in-line with consensus.
- SanBio’s cash position improved with cash and cash equivalents of ¥6.7B at the end of FY23, up from ¥4.6B at the end of the previous fiscal year.
- The company aims to obtain approval of its lead candidate SB623 as a treatment for chronic motor deficit from traumatic brain injury during the current fiscal year.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- SanBio Co Ltd (4592 JP): Losses Narrow; AKUUGO Upbeat on Successful Commercial Runs; FY26 Key19 Mar 2025
- SanBio Co Ltd (4592 JP): Conditional Approval for First Drug; Still a Long Way to Go20 Sep 2024
- SanBio (4592 JP): Better-Than-Expected Operating Loss in FY23; Product Approval Expected in FY2417 Mar 2023
- SanBio (4592 JP): Remains Unlucky for Second-Time; Delay in First Product Approval Weighs Heavily02 Nov 2022
- SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan15 Apr 2022
x